Matisse Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Matisse Capital’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-58,000	Closed	-$620K	–	114
2018 Q4	$620K	Hold	58,000	–	–	0.78%	34
2018 Q3	$885K	Buy	58,000 +1,000	+2%	+$14.6K	0.79%	36
2018 Q2	$698K	Hold	57,000	–	–	0.55%	54
2018 Q1	$545K	Sell	57,000 -43,000	-43%	-$464K	0.33%	72
2017 Q4	$903K	Hold	100,000	–	–	0.41%	61
2017 Q3	$575K	Buy	+100,000	New	+$364K	0.27%	66

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Matisse Capital's DRNA Position: Q1 2019 in Review

Matisse Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2019, closing a stake of 58,000 shares — an estimated $620K sold.

Matisse Capital first reported a position in DRNA in Q3 2017 and held it in 6 quarters. The position peaked at $903K in Q4 2017. 98 funds tracked by Wall St. Rank hold DRNA as of Q1 2019.

Matisse Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Matisse Capital sold 58,000 Dicerna Pharmaceuticals, Inc. shares in Q1 2019, an estimated $620K.
Matisse Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2017 and held it in 6 quarters.
Matisse Capital's Dicerna Pharmaceuticals, Inc. position peaked at $903K in Q4 2017.
98 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2019.

Based on Matisse Capital's 13F filing for Q1 2019, filed 24 Apr 2019.